Portfolio AOP Health
A Product overview with focus on Rare Diseases.
AOP Health's focus is on integrated therapies for rare diseases and in critical care. The portfolio comprises products in the following therapeutic areas: Hemato-oncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders and Critical Care. AOP Health’s strategic goal is to constantly deliver new treatment options with respect to rare diseases and critical care.
Adepend is used as part of a comprehensive treatment programme against alcoholism to reduce the risk of relapse, as support treatment in abstinence and to reduce the craving for alcohol.
"Argipressin based vasopressor indicated for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory/resistant hypotension is present if the mean arterial blood pressure cannot be stabilized to >65 mmHg despite adequate volume substitution and application of catecholamines."
Empressin® is used for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory hypotension is present if the mean arterial blood pressur cannot be stabilized to 65 – 75 mmHg despite adequate volume substitution and application of catecholamines.
Feraccru® is indicated for adults for the treatment of iron deficiency.
Motetis® is used as symptomatic therapy in the treatment of hyperkinetic motor disorders in Huntington’s disease. Tetrabenazine is also used in etiologist such as tardive dyskinesia, tics and dystonia.
"for short-term relief of moderate to severe pain. E.g. post-surgery, in labour pain and gynaecology, in myocardial infarction. Antagonizing an opioid induced respiratory depression, e.g. following fentanyl-combined narcosis. use in a combined narcosis ."
"Complete or partial reversal of CNS depressive effects, especially respiratory depression, caused by natural or synthetic opioids and partial agonist/antagonist opioids. It is also used to diagnose a suspected acute opioid overdose or intoxication or to reduce the effect of opioids, which were used for anesthesia in operations."
Ocaliva® is indicated for the treatment of primary biliary cholangitis (also known to as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.
Landiolol hydrochloride is indicated for supraventricular tachycardia and for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable. Landiolol hydrochloride is also indicated for non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention. Landiolol is not intended for use in chronic settings.
Tadalafil AOP is used to treat adults with pulmonary arterial hypertension (PAH) to improve exercise capacity (the ability to carry out physical activity).
Thromboreductin® is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients